Published in Am J Epidemiol on January 01, 1976
Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol (2003) 1.95
Simian virus 40 infection of humans. J Virol (2003) 1.71
Simian virus 40 and human pleural mesothelioma. Thorax (1999) 1.56
Ethnic differences in polyomavirus simian virus 40 seroprevalence among women in Houston, Texas. J Infect (2012) 1.52
Comparing phylogenetic codivergence between polyomaviruses and their hosts. J Virol (2006) 1.25
Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue. Thorax (1996) 1.22
Emergent human pathogen simian virus 40 and its role in cancer. Clin Microbiol Rev (2004) 1.10
Simian virus 40 in humans. Infect Agent Cancer (2007) 1.09
Episomal simian virus 40 genomes in human brain tumors. Proc Natl Acad Sci U S A (1981) 1.06
Presence of allograft-rejection resistance in simian virus 40-transformed hamster cells and its possible role in tumor development. Proc Natl Acad Sci U S A (1980) 1.04
High incidence of SV40-like sequences detection in tumour and peripheral blood cells of Japanese osteosarcoma patients. Br J Cancer (2000) 0.98
Patterns of polyomavirus SV40 infections and associated cancers in humans: a model. Curr Opin Virol (2012) 0.96
Simian virus 40 and human malignancy. BMJ (1998) 0.96
An update on nonmelanoma skin cancer. J Clin Aesthet Dermatol (2011) 0.95
Infectious disease issues in xenotransplantation. Clin Microbiol Rev (2001) 0.91
Thirty-five year mortality following receipt of SV40- contaminated polio vaccine during the neonatal period. Br J Cancer (2001) 0.86
Molecular identification of simian virus 40 infection in healthy Italian subjects by birth cohort. Mol Med (2006) 0.86
Virus contaminations of cell cultures - A biotechnological view. Cytotechnology (2002) 0.85
Serodiagnosis for tumor viruses. Semin Oncol (2014) 0.85
Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J Natl Cancer Inst (1999) 0.84
Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40. Orphanet J Rare Dis (2006) 0.84
Fanconi anemia patients are more susceptible to infection with tumor virus SV40. PLoS One (2013) 0.83
Nuclear factor of activated T-cells (NFAT) plays a role in SV40 infection. Virology (2007) 0.81
Political refutation of a scientific theory: the case of polio vaccines and the origin of AIDS. Health Care Anal (1998) 0.81
Review on the relationship between human polyomaviruses-associated tumors and host immune system. Clin Dev Immunol (2012) 0.81
Influence of the viral regulatory region on tumor induction by simian virus 40 in hamsters. J Virol (2007) 0.80
SV40-immortalized human fibroblasts as a source of SV40 infectious virions. Mol Med (2006) 0.80
Adventitious viral genomes in vaccines but not in vaccinees. Emerg Infect Dis (2001) 0.79
Neutralizing and IgG antibodies against simian virus 40 in healthy pregnant women in Italy. PLoS One (2014) 0.78
Specific Antibodies Reacting with SV40 Large T Antigen Mimotopes in Serum Samples of Healthy Subjects. PLoS One (2016) 0.77
SV40 Tag DNA sequences, present in a small proportion of human hepatocellular carcinomas, are associated with reduced survival. J Clin Pathol (2003) 0.77
Investigating the origin of AIDS: some ethical dimensions. J Med Ethics (2003) 0.75
Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis. Vaccine (2016) 0.75
Role of the C-terminal region of vervet monkey polyomavirus 1 VP1 in virion formation. J Vet Med Sci (2014) 0.75
The nature of the principal type 1 interferon-producing cells in human blood. Science (1999) 10.90
An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol (1992) 4.85
Requirement for theta-bearing cells in lymphocytic choriomeningitis virus-induced central nervous system disease. Nature (1972) 4.08
Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy. N Engl J Med (1972) 3.09
Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci U S A (1996) 2.81
Immunopathogenesis of acute central nervous system disease produced by lymphocytic choriomeningitis virus. II. Adoptive immunization of virus carriers. J Exp Med (1972) 2.68
Seasonality and the requirements for perpetuation and eradication of viruses in populations. Am J Epidemiol (1979) 2.58
Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis (2001) 2.51
Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. Br J Pharmacol (1992) 2.50
Immunologic relatedness of papillomaviruses from different species. J Natl Cancer Inst (1980) 2.44
Immunopathogenesis of acute central nervous system disease produced by lymphocytic choriomeningitis virus. I. Cyclophosphamide-mediated induction by the virus-carrier state in adult mice. J Exp Med (1972) 2.37
Design of allele-specific inhibitors to probe protein kinase signaling. Curr Biol (1998) 2.36
Imaging findings of extraventricular neurocytoma: report of 3 cases and review of the literature. AJNR Am J Neuroradiol (2008) 2.30
Laparoscopic kidney transplantation: an initial experience. Am J Transplant (2011) 2.24
Potentiation of experimental arbovirus encephalitis by immunosuppressive doses of cyclophosphamide. Nature (1968) 2.16
ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat Cell Biol (2001) 2.14
Arterial embolization is a rapid and effective technique for controlling pelvic fracture hemorrhage. J Trauma (1997) 2.12
Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer (1997) 2.06
The genetics of susceptibility to multiple sclerosis. Epidemiol Rev (1982) 2.00
Unnatural ligands for engineered proteins: new tools for chemical genetics. Annu Rev Biophys Biomol Struct (2000) 1.99
Human papillomaviruses in women with a history of abnormal Papanicolaou smears and in their male partners. Obstet Gynecol (1987) 1.97
Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc Natl Acad Sci U S A (1993) 1.96
Pathogenesis of visna. I. Sequential virologic, serologic, and pathologic studies. Lab Invest (1976) 1.96
The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am J Epidemiol (1979) 1.87
Engineering Src family protein kinases with unnatural nucleotide specificity. Chem Biol (1998) 1.81
Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol (1997) 1.80
Immunosuppression and experimental virus infection of the nervous system. Adv Virus Res (1970) 1.79
Lymphocytic choriomeningitis virus: pathogenesis of acute central nervous system disease. Fed Proc (1972) 1.66
Macrophage-tropic strains of human immunodeficiency virus type 1 utilize the CD4 receptor. J Virol (1990) 1.65
Fatal Japanese encephalitis virus infection in immunosuppresed spider monkeys. Clin Exp Immunol (1970) 1.61
The value to the anesthesia-surgical care team of the preoperative cardiac consultation. J Cardiothorac Anesth (1989) 1.61
The effect of soft cervical collars on persistent neck pain in patients with whiplash injury. Acad Emerg Med (1996) 1.61
Hepatitis B infection in households of chronic carriers of hepatitis B surface antigen: factors associated with prevalence of infection. Am J Epidemiol (1982) 1.60
Identification to the species level and differentiation between strains of Aspergillus clinical isolates by automated repetitive-sequence-based PCR. J Clin Microbiol (2004) 1.59
Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol (2000) 1.57
Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J Infect Dis (1974) 1.51
Thrombocytopenia and human immunodeficiency virus in children. Pediatrics (1988) 1.49
Lymphocytic choriomeningitis. Pathogenesis. Prog Med Virol (1974) 1.47
The oral management of patients who have received radiotherapy to the head and neck region. Br Dent J (2013) 1.46
Mechanisms of bunyavirus virulence. Comparative pathogenesis of a virulent strain of La Crosse and an avirulent strain of Tahyna virus. Lab Invest (1984) 1.44
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. Ann Oncol (2012) 1.44
Analysis of the extractive and hydrolytic behavior of microthane poly(ester-urethane) foam by high pressure liquid chromatography. J Biomed Mater Res (1993) 1.42
Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res (1997) 1.42
Experimental infection of monkeys with Langat virus II. Turnover of circulating virus, 1967. Rev Med Virol (2000) 1.42
Pathogenesis of visna. II. Effect of immunosuppression upon early central nervous system lesions. Lab Invest (1976) 1.42
Eradication of poliomyelitis in the United States. Rev Infect Dis (1983) 1.42
Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer (2009) 1.40
Identification of new JNK substrate using ATP pocket mutant JNK and a corresponding ATP analogue. J Biol Chem (2001) 1.39
Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial. Br J Ophthalmol (2006) 1.37
Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br J Pharmacol (2001) 1.35
Experimental encephalitis following peripheral inoculation of West Nile virus in mice of different ages. J Hyg (Lond) (1970) 1.34
Pathogenesis of West Nile Virus encepahlitis in mice and rats. II. Virus multiplication, evolution of immunofluorescence, and development of histological lesions in the brain. Am J Epidemiol (1967) 1.31
An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol (1984) 1.30
Pathogenesis of West Nile Virus encephalitis in mice and rats. 1. Influence of age and species on mortality and infection. Am J Epidemiol (1967) 1.28
Organization of the middle RNA segment of snowshoe hare Bunyavirus. Virology (1988) 1.26
Clinical guidelines to diagnose smear-negative pulmonary tuberculosis in Pakistan, a country with low-HIV prevalence. Trop Med Int Health (2006) 1.25
Histological studies of the monkey neurovirulence of group B arboviruses. I. A semiquantitative grading scale. Am J Epidemiol (1965) 1.24
Human immunodeficiency virus type 1 causes productive infection of macrophages in primary placental cell cultures. J Infect Dis (1994) 1.24
Opportunistic infections in acquired immune deficiency syndrome result from synergistic defects of both the natural and adaptive components of cellular immunity. J Clin Invest (1986) 1.23
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene (2007) 1.23
Characterization of monoclonal antibodies against the G1 and N proteins of LaCrosse and Tahyna, two California serogroup bunyaviruses. Virology (1982) 1.23
A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorg Med Chem (1998) 1.23
Genital tract papillomavirus infection in children. Arch Dermatol (1986) 1.21
Pathogenesis of cerebellar hypoplasia produced by lymphocytic choriomeningitis virus infection of neonatal rats. 1. Evolution of disease following infection at 4 days of age. J Neuropathol Exp Neurol (1973) 1.21
Key factors in the optimization of paediatric X-ray practice. Br J Radiol (2001) 1.21
Social differences in sexual behaviour and cervical cancer. IARC Sci Publ (1997) 1.20
Specific identification of human papillomavirus type in cervical smears and paraffin sections by in situ hybridization with radioactive probes: a preliminary communication. Int J Gynecol Pathol (1985) 1.19
The role of antibody in recovery from experimental rabies. I. Effect of depletion of B and T cells. J Immunol (1978) 1.19
Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol (1999) 1.19
A multifaceted study of human papillomavirus and prostate carcinoma. Cancer (1998) 1.18
Acute rabies death mediated by antibody. Nature (1981) 1.17
The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg (2000) 1.17
Completion of the La Crosse virus genome sequence and genetic comparisons of the L proteins of the Bunyaviridae. Virology (1995) 1.16
Engineering of the myosin-ibeta nucleotide-binding pocket to create selective sensitivity to N(6)-modified ADP analogs. J Biol Chem (1999) 1.14
Hyaluronic acid skin fillers: adverse reactions and skin testing. J Am Acad Dermatol (2001) 1.14
Surface vs core-tonsillar aerobic and anaerobic flora in recurrent tonsillitis. JAMA (1980) 1.13
Expression of the La Crosse M segment proteins in a recombinant vaccinia expression system mediates pH-dependent cellular fusion. Virology (1993) 1.13
Protection from La Crosse virus encephalitis with recombinant glycoproteins: role of neutralizing anti-G1 antibodies. J Virol (1995) 1.13
Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration. Lupus (2003) 1.13
Electrocardiographic J waves after resuscitation from cardiac arrest. Chest (1990) 1.13
An avirulent G1 glycoprotein variant of La Crosse bunyavirus with defective fusion function. J Virol (1985) 1.12
Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum Pathol (1999) 1.11
Heterotopic cerebellar granule cells following administration of cyclophosphamide to suckling rats. Brain Res (1969) 1.11
Bacteriology of adenoids and tonsils in children with recurrent adenotonsillitis. Ann Otol Rhinol Laryngol (2001) 1.10
p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am J Pathol (1993) 1.09
A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope (1992) 1.09
Immunosuppression: a means to assess the role of the immune response in acute virus infections. Fed Proc (1972) 1.09
Molecular determinants of the virulence and infectivity of California serogroup bunyaviruses. Annu Rev Microbiol (1993) 1.08
Antigenic drift in visna: virus variation during long-term infection of Icelandic sheep. J Gen Virol (1983) 1.07
Thanatophoric dwarfism. J Med Genet (1973) 1.06
The interaction between i.v. theophylline and chronic oral dosing with slow release nifedipine in volunteers. Br J Clin Pharmacol (1986) 1.06
Experimental visna in Icelandic sheep: the prototype lentiviral infection. Rev Infect Dis (1985) 1.06
Cloning of a cysteine protease required for the molting of Onchocerca volvulus third stage larvae. J Biol Chem (1996) 1.05
Evaluation of the home-based maternal record: a WHO collaborative study. Bull World Health Organ (1993) 1.04
Serological Investigation of the possibility of congenital transmission of papovavirus JC. Infect Immun (1981) 1.04
Serological investigation of BK papovavirus infection in pregnant women and their offspring. Infect Immun (1980) 1.04
Neuroattenuation of an avirulent bunyavirus variant maps to the L RNA segment. J Virol (1991) 1.03
Engagement of commissioners, primary and secondary care for developing successful ADHD services. Eur Child Adolesc Psychiatry (2013) 1.03